+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 44 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.

Age: 50Years +All GendersPhase 2Phase 3
132 locations
E

Actively Recruiting

Researchers are investigating new treatments for diabetic macular edema DME, a condition that can cause vision loss. This trial aims to compare the effects of a new medicine called MK-8748 with the current standard treatment, aflibercept, to see if MK-8748 works as well. The study focuses on adults with type 1 or type 2 diabetes who have vision decrease due to DME. Participants will be randomly assigned to one of three groups two groups receive different doses of MK-8748 via injections into the eye, starting with five doses every 4 weeks, then every 8 weeks until week 48, followed by treatment intervals based on individual response up to week 100. The third group receives aflibercept injections on a similar schedule for up to 100 weeks. The study is double-masked and multicenter, designed to carefully compare these treatments. During the trial, participants will have regular eye examinations, including measurements of visual acuity and retinal thickness, along with imaging tests such as optical coherence tomography and fluorescein angiography. Researchers will monitor changes in vision and eye condition over one to two years, assess treatment safety, and track adverse events and drug levels. The main outcome measured is the change in best-corrected visual acuity after one year of treatment.

Age: 18Years +All GendersPhase 3
35 locations
P

Actively Recruiting

Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.

Age: 60Years +All GendersPhase 2
78 locations
R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations
S

Actively Recruiting

Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.

Age: 18Years +All GendersPhase 3
364 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness of AXS-05 compared to bupropion in preventing the return of depressive symptoms in adults with major depressive disorder MDD who have already responded to treatment with AXS-05. This is a randomized, double-blind, active-controlled study conducted across multiple centers, aiming to assess relapse prevention in people diagnosed with MDD without psychotic features. Participants will first receive open-label AXS-05 treatment for up to 10 weeks, during which their response and remission will be monitored. Those who meet response and remission criteria will then be randomly assigned to continue taking AXS-05 or switch to bupropion tablets, both taken twice daily, for a double-blind treatment period lasting up to 26 weeks or until depressive symptoms relapse. Throughout the study, participants will be closely monitored for signs of depressive symptom relapse using regular assessments. The main outcome measured is the time from randomization to relapse over the 26-week double-blind period. The entire study period includes an initial 10-week treatment phase followed by up to 26 weeks of randomized treatment, with ongoing evaluation by the study team to track safety and treatment effects.

Age: 18Years - 65YearsAll GendersPhase 4
40 locations
E

Actively Recruiting

Researchers are studying a treatment for adults with muscle-invasive bladder cancer, a condition where cancer has spread into the muscle wall of the bladder. The usual approach involves chemotherapy followed by bladder removal surgery, which can cause significant long-term changes. This study focuses on using a combination of enfortumab vedotin and pembrolizumab to help people keep their bladder, especially for those who respond well to this therapy and wish to avoid surgery. Participants will receive infusions of enfortumab vedotin on the 1st and 8th days of every 3-week cycle, along with pembrolizumab on the 1st day of each cycle. Treatment continues unless the cancer worsens, does not improve after 9 cycles, or if other medical reasons arise. Those whose cancer does not respond may need surgery, radiotherapy, or chemotherapy. The study monitors safety and tumor status regularly during these cycles. Throughout the study, participants will have safety checks at each visit, tumor assessments at some visits, and medical monitoring. After stopping treatment, health checks and scans occur every 3 months for 2 years, then every 6 months for up to 5 years if the cancer remains stable. Once cancer progresses, scans stop, but telephone health checks continue every 3 months. The main outcomes measured are the rate of complete response to treatment and the duration participants keep their bladder intact over two years.

Age: 18Years +All GendersPhase 2
68 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of centanafadine extended-release capsules taken once daily in adults who have attention-deficithyperactivity disorder ADHD along with emotional dysregulation ED. This Phase 3b, open-label study aims to understand how this treatment may affect symptoms of ADHD and emotional regulation in this population. The trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. and includes adults aged 18 to 65 years. Participants in this study will receive centanafadine XR capsules at a dose of 328.8 milligrams orally once daily for eight weeks. This single-group trial does not include a placebo or comparator group. The treatment period lasts for eight weeks, during which participants take the study drug daily to assess its effects on ADHD and emotional dysregulation symptoms. During the study, participants will be monitored through various assessments including the Wender-Reimherr Adult Attention Deficit Disorder Scale WRAADDS, Clinical Global Impressions for ADHD severity, executive function evaluations, and emotional regulation scales. Safety is also monitored by tracking adverse events and suicidal ideation or behavior. The main outcome measure assesses changes in ADHD symptoms over the eight-week treatment period, with study participation lasting approximately two months.

Age: 18Years - 65YearsAll GendersPhase 3
16 locations
C

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of a fixed dose of SEP-363856 compared to placebo in adults with generalized anxiety disorder GAD. This global, phase 3, randomized, double-blind, placebo-controlled trial aims to provide new information about treatment options for adults diagnosed with GAD. Participants are randomly assigned to receive either SEP-363856 or a matching placebo. Those in the active treatment group start with 50 mg of SEP-363856 daily for the first 3 days, then increase to 75 mg daily for the remainder of the 8-week treatment period. The placebo group receives a matching tablet daily for 8 weeks. Both treatments are taken orally once a day. During the study, participants undergo assessments that include evaluations of anxiety symptoms using the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression-Severity CGI-S scale. Researchers monitor changes from baseline to week 8 in these scores to assess treatment impact. Safety and tolerability are also monitored throughout the trial. Participation lasts for the 8-week treatment period with regular visits as scheduled.

Age: 18Years +All GendersPhase 3
11 locations

1-10 of 44

1